Adam Gregory

Adam builds patent portfolios and co-ordinates their prosecution worldwide. He enjoys taking the time to understand his clients’ technologies and commercial goals, and working with them to develop an appropriate supporting IP strategy.  Adam also works with venture capital companies to help them evaluate investment opportunities. He has particular experience working with technologies in the fields of cell therapy, gene therapy, antibody technology, immunotherapy, longevity technology and cellular agriculture/alternative protein.

Adam is particularly well-known in the thriving Singapore Life Sciences scene, where he works for a large number of biotech companies. 

Areas of Technical Expertise

• Immunology
• Molecular and Cellular Biology
• Cancer
• Neurology
• Infectious and Autoimmune disease
• Cell culture
• Stem cell technology
• Genetic engineering

Clients

Adam’s clients are based in Singapore, Europe and the US, and include biotech start-ups and SMEs, academic institutions, governmental organisations and multinational biotech corporations.

Background

Adam has a D.Phil in Clinical Medicine and a first class undergraduate degree in Biological Sciences, both from the University of Oxford.

He joined Mewburn Ellis LLP in 2012, qualifying as a Chartered Patent Attorney and a European Patent Attorney in 2016, and became a Partner in 2020.

Recommendations

Adam has been listed as a "key lawyer" in the 2021 and 2023-2024 editions of The Legal 500.